IMPORTANCE Hepatitis E virus (HEV) recently has been shown to be an antecedent infection in Guillain-Barré syndrome (GBS), but the clinical spectrum of HEV-associated GBS is not yet documented, and diagnosing acute HEV infection can be a challenge.
G uillain-Barré syndrome (GBS) is characterized in its classic form by a rapidly progressive bilateral and relatively symmetric weakness of the limbs with or without involvement of respiratory muscles or muscles innervated by the cranial nerves, with a maximum level of weakness reached within 4 weeks. 1 Many clinical variants of GBS have been described according to the regional distribution of weakness (eg, limbs, ocular, or bulbar) or the relative involvement of motor vs sensory nerves. A postinfectious, immune-mediated disorder of the peripheral nerves and nerve roots is the most likely disease mechanism for GBS. 1 Studies in humans and animals have provided convincing evidence that at least some cases of GBS are caused by an infection-induced aberrant immune response that damages the peripheral nerves. [2] [3] [4] [5] [6] [7] [8] [9] About two-thirds of patients have symptoms of an infection in the 3 weeks before the onset of weakness. The most common infectious causes of GBS are
Campylobacter jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), Mycoplasma pneumoniae, and Haemophilus influenzae. 10, 11 An association between infection with hepatitis E virus (HEV) and GBS has been suspected in several case reports and retrospective cohort studies of patients with HEV infection. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] In 2013, a prospective case-control study reported positive IgM antibodies against HEV in 11% of patients with GBS in Bangladesh. 30 A second case-control study identified an associated acute HEV infection in 5% of patients with GBS in the Netherlands.
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Hepatitis E virus is a nonenveloped RNA virus belonging to the Hepeviridae family that has an icosahedral capsid and 3 open reading frames. Four HEV genotypes have been described. It is a common virus that is the most frequent cause of viral hepatitis worldwide and is endemic in one-third of the world population. In the Western world, HEV genotypes 3 and 4 are principally transmitted zoonotically to humans from an animal reservoir (eg, domesticated pig, wild boar, deer, and rabbits) by eating undercooked meat or via contaminated water. [32] [33] [34] Infection with HEV has been associated with many neurological diseases apart from GBS, such as neuralgic amyotrophy, [35] [36] [37] [38] [39] In this study, we retrospectively assessed the prevalence of acute HEV infection in a cohort of Belgian patients with GBS or a variant of GBS and compared this prevalence with other infections known to be associated with GBS. Furthermore, we explored GBS disease parameters that are specific to HEV.
Methods

Patients
We searched the electronic medical records to identify all patients with GBS or a variant of GBS who presented to the adult neurology department of the University Hospital Leuven between January 1, 2007, and November 1, 2015 . All patients with a diagnosis of GBS or a variant who presented within the first 4 weeks after the onset of neurological symptoms were included. Using criteria described in the literature, all patients were divided into the following clinical categories: pure motor GBS, Miller-Fisher syndrome, Bickerstaff brainstem encephalitis, acute ataxic neuropathy, bifacial weakness with distal paresthesias, acute multiple cranial neuropathic conditions, pharyngeal-cervical-brachial variant, and overlap syndromes (eAppendix 1 in the Supplement).
52-61 We excluded patients who were transferred to our hospital after administration of intravenous immunoglobulins as well as patients without a usable serum sample in the laboratory serum bank. This study was approved by the ethical committee and the biobank of the University Hospital Leuven. As this was a retrospective study, the University Hospital Leuven Institutional Review Board did not require informed consent. We recorded the following clinical features from the medical records: date of onset of neurological symptoms, date of onset and type of antecedent infection, age at onset, sex, immune status before symptom onset, clinical variant of GBS, cranial nerve involvement, immunomodulatory treatment, need for intubation, and GBS disability score at nadir and after 3 to 6 months. 62 If present, the following laboratory results were recorded: alanine aminotransferase (ALT) and total bilirubin levels at admission or highest level before presentation and before the start of any medical therapy, date and results of lumbar puncture, presence of anti-ganglioside or antisulfatide antibodies (IgM and IgG against GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b, and sulfatides), and infectious serologic tests in serum and stool cultures. 
Microbiological Testing on Stored Sera
Serum samples-aliquoted, stored at -20°C, and collected before the administration of intravenous immunoglobulinswere retrieved from the laboratory serum bank and used for HEV serologic testing. All samples were previously tested for IgG and IgM for CMV as part of the routine diagnostic workup. Serologic testing for H influenzae was not routinely performed.
Testing for HEV was performed as follows. First, an enzyme immunoassay (EIA) was performed (recomWell HEV IgM/ IgG enzyme immunoassay, MIKROGEN Diagnostik) following the manufacturer's recommendations: positive when the results are above 24 U/mL, equivocal when they are between 20 and 24 U/mL, and negative when they are less than 20 U/mL. In cases of equivocal reactivity for HEV IgM or in the case of concurrent presence of positive serologic findings for other infectious agents (ie, CMV or EBV) and an equivocal or positive EIA result for HEV IgM, a confirmatory recombinant immunoblot test (RIBT) for HEV IgM (recomLine HEV IgM, MIKROGEN Diagnostik) and EIA for HEV IgM and IgG on later serum samples was performed, with remaining serum samples (if available) sent to the Belgian Scientific Institute of Public Health for HEV reverse transcriptase polymerase chain reaction (RT-PCR) (RealStar HEV RT-PCR kit 1.0, Altona Diagnostics). An acute HEV infection was considered possible in the case of positive results on anti-HEV IgM EIA and/or positive results on anti-HEV IgM RIBT. In cases with positive serologic markers for anti-HEV IgM and other pathogens, RT-PCR for those other pathogens was performed on the serum samples used for HEV assays to exclude false anti-HEV reactivity by these agents. Probable acute HEV infection was defined as possible infection in the absence of significant cross-reactivity to other pathogens. The additional presence of anti-HEV IgG antibodies or positive results on RT-PCR for HEV on serum samples was considered as suggestive of a definite HEV infection.
Statistical Analysis
Data are presented as medians (ranges) or means (SDs). Normal distribution of data sets was determined with the Shapiro-Wilk normality test. A t test was used to compare the quantitative variables if they were normally distributed. A 2-tailed, unpaired Mann-Whitney test was used if variables were not normally distributed. P < .05 was considered significant.
Results
We identified 88 patients with GBS or a variant of GBS, of which 73 fulfilled our inclusion criteria (Figure) . Two of the 88 patients were excluded because they had no serum sample before the start of intravenous immunoglobulins, and a third patient was excluded because no serum sample was available.
The demographic and clinical characteristics of our cohort, as well as results of laboratory tests, NCS, and electromyography, are summarized in Table 1 .
63 Classic GBS and acute inflammatory demyelinating polyneuropathy were the most common clinical and electrophysiologic variants, respectively. Three patients had acute motor axonal neuropathy associated with C jejuni median delay between symptom onset and serum sampling was 7 days (range, 0-31 days). The results of HEV serologic testing in our cohort are presented in the Figure. When assessing possible acute HEV infection preceding GBS, we found positive anti-HEV IgM on EIA and/or RIBT in 6 patients (8%). Of those, 4 (67%) had ALT levels more than 1.5 times the upper limit of normal. We found no significant age difference between patients with anti-HEV IgM antibodies vs those without such antibodies (mean age, 61 vs 52 years; P = .12). Thirteen patients (18%) had positive IgG serologic findings for HEV.
The characteristics of patients with a possible acute HEV infection are presented in Table 2 .
63 There was a striking heterogeneity in phenotypes observed. Patient 1 presented with an acute ataxic neuropathy, which was previously described in more detail. 64 Patient 3 developed rapidly progressive, painful paresthesia and paresis in both arms, with development of scapular winging on the right side, only 1 day after reporting general discomfort and fever. Consecutive NCS and the electromyogram showed signs of progressive axonal loss in both sensory and motor nerves in both arms. The patient developed global areflexia, paralysis of the vocal cords on the left k The following anti-ganglioside antibodies (IgG and IgM) were tested: ganglioside GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b, and sulfatides.
l Demyelinating features, but insufficient for criteria for acute inflammatory demyelinating polyneuropathy. No later time points were available for serologic study. The patient had a classic presentation of GBS, with demyelinating features seen on NCS, without elevation of ALT levels. The patient never received mechanical ventilation. He died after cardiac arrest 1 month after the onset of neurological symptoms. No autopsy was performed. The patient had a medical history of ischemic and valvular cardiomyopathy, complicated with episodes of ventricular tachycardia, for which a cardioverter defibrillator had been implanted.
Patient 5 had a classic presentation of GBS. She had a positive serologic result for anti-HEV IgG and borderline or equivocal anti-HEV IgM EIA results but a positive serologic result for anti-HEV IgM RIBT and increased ALT levels. She had a borderline value for IgM against M pneumoniae, which was deemed not relevant. Results of RT-PCR performed on serum samples for M pneumoniae were negative.
The last 2 patients with positive HEV serologic findings also tested positive for other pathogens. Patient 2 developed mild GBS, with predominantly sensory symptoms (paresthesia and pain) and mild paresis (limbs and mild dysarthria) without We found no significant correlations between clinical parameters and the presence of HEV antibodies. Results of antiganglioside and anti-sulfatide antibody testing were negative in all 6 patients with HEV IgM antibodies. Four of the 6 patients had ALT levels more than 1.5 times the upper limit of normal. Bilirubin levels were slightly elevated in 3 patients and were significantly elevated in 1 patient with icterus.
We studied the contribution of HEV infection to elevated ALT levels 65 in the entire cohort and found 22 patients with elevated (>1.5 times the upper limit of normal) ALT levels. In 8 of those cases (36%), positive anti-CMV IgM reactivity was found. The second most common finding was a possible acute HEV infection seen in 4 patients (18%). One patient demonstrated positive reactivity for EBV and 1 for M pneumoniae.For patients with positive serologic markers for multiple pathogens, every pathogen was counted. Of the 36 patients with normal ALT levels, 1 (3%) had HEV IgM antibodies (patient 6). Of the 51 patients with ALT levels less than 1.5 times the upper limit of normal, 2 (4%) had positive HEV IgM serologic findings (patients 2 and 6).
Discussion
The demographic and clinical characteristics, as well as results of laboratory tests, NCS, and electromyography, of our cohort of patients with GBS were comparable with those of earlier published cohorts. Guillain-Barré syndrome affected males 1.5 times more often than females. 1, 66 The mean age in our cohort was slightly higher than anticipated, but this finding may be owing to the fact that we did not include children. 66 Similar to findings in previous reports, the sensory-motor (classic) variant of GBS was the most frequent, seen in 77% of patients, compared with rates of 75% to 80% in an earlier study. 54 We found antibodies to various gangliosides and sulfatides in only 16 patients (22%), while other studies have reported the presence of those antibodies in about half of the patients with GBS or variants. 1 In several case reports of GBS with associated HEV infection, anti-ganglioside antibodies to GM1 or GM2 were found. 14, 15, 17, 24, 25, 28 In line with a larger case-control series with 10 patients, 31 none of the HEV-associated cases in our cohort had anti-ganglioside or anti-sulfatide antibodies. An acute demyelinating neuropathy was the most frequent electrophysiologic variant in our cohort. Only 7% of patients had an axonal variant (acute motor axonal neuropathy or acute motor and sensory axonal neuropathy), which is similar to findings in other reports. 66 In line with other studies, we also observed that most patients with Miller-Fisher syndrome or Bickerstaff brainstem encephalitis had no or only slight abnormalities on results of NCS. Overall, our cohort has the characteristics of a representative sample of patients with GBS and variants. The seroprevalence of anti-HEV IgG in our cohort is lower (18%) than that found in a cohort with GBS from the Netherlands (46%). 31 Moreover, they found no significant difference in seroprevalence between controls and the patients with GBS. The exact seroprevalence of anti-HEV IgG in Belgium is not known, but our value in patients with GBS or a variant was similar to the seroprevalence of 14% seen in a small cohort of Belgian orthopedic and obstetric patients. 67 This percentage is lower than findings, mostly in blood donors, from the Netherlands (27%), Germany (29%), Bangladesh (50%), and southwest France (34%-52%), 31,68 and suggests that important locoregional differences in HEV prevalence occur. We found that 8% of our patients had positive anti-HEV IgM on EIA and/or RIBT, indicating a possible acute HEV infection. This rate is lower than that in a cohort of patients with GBS from Bangladesh (11%), where HEV is endemic, 30 but higher than the rate found in a Dutch cohort (5% One of the most important diagnostic challenges we encountered, which was not fully addressed in previous studies, was the co-occurrence of positive results of infectious serologic tests for different pathogens at the same time. The limit value of M pneumoniae in patient 5 was deemed irrelevant, and cross-reactivity between HEV and M pneumoniae also has not been described. We thus retain patient 5 as a case of definite acute HEV infection. Patients 2 and 4, however, had positive serologic results for CMV or EBV IgM and IgG. Crossreactivity on serologic tests between HEV, CMV, and EBV has been described, giving rise to false-positive results of HEV IgM owing to CMV or EBV infection or giving rise to false-positive results of CMV or EBV IgM owing to HEV infection. [69] [70] [71] This cross-reactivity is mentioned in the manufacturer's instructions for the recomLine test. Cross-reactivity with EBV, but not with CMV, is described in the manufacturer's instructions for the recomWell test. However, cross-reactivity with CMV when using the older version of the test has been described. 69 These issues suggest that the assays are not perfect and that it is difficult to obtain a definite diagnosis in some patients. It is our hope that further refinement of the immunoassays will eliminate the issue of cross-reactivity in the future. This refinement might also help in resolving the possibility of a coinfection. Since patient 4 had a positive result for RT-PCR performed on serum samples for CMV, she probably had an acute CMV infection or reactivation of CMV. Taking these factors into account, we had 4 cases (6%) of definite or probable acute HEV infection in our cohort (excluding patients 2 and 4, not 4 and 6, when following the serologic criteria from the Dutch cohort
31
). Similar to an older report in the literature, 65 we observed elevated liver enzymes in about one-third of the patients with GBS. Eight of these patients (36%) had positive reactivity for CMV IgM. Reactivity for HEV IgM appears to be the second most common finding in patients with GBS who have elevated ALT levels, seen in 18% of our cohort. When examining only cases of probable or definite acute HEV infection in our cohort, 3 of 22 patients (14%) had significant elevation of ALT levels. This finding suggests that HEV is the second most common cause of elevated ALT levels in patients with GBS. However, not all patients with HEV-associated GBS have elevated ALT levels. Therefore, testing for HEV should be considered in patients with normal liver enzyme levels.
Limitations
Our study has several limitations. As it is a retrospective study, not every patient received the same diagnostic workup. Another limitation was the absence in particular cases of follow-up serum samples at later time points, which could have helped to demonstrate seroconversion.
Conclusions
Acute HEV infection was frequently associated with GBS or variants of GBS in our cohort. Depending on the stringency of the definition of HEV positivity, 8% or 6% tested positive. The phenotypes associated with GBS ranged widely from classic GBS to a pharyngeal-cervical-brachial variant and a sensory ataxic variant. Abnormal ALT levels at admission can indicate an associated HEV infection. Testing for other infectious agents in parallel is important since crossreactivity with EBV and CMV is possible with current assays. Performing RT-PCR to detect viral nucleic acids does not always allow us to make definitive conclusions, as the test results may be negative owing to the short viremia in an acute HEV infection. Further studies are required to guide neurologists in their workup of the underlying causes of GBS. For the diagnosis of this condition, the following should be excluded: acute spinal cord disease, carcinomatous or lymphomatous meningitis, myasthenia gravis, botulism, critical illness neuropathy, thiamine deficiency, periodic paralysis, corticosteroid-induced myopathy, toxins (such as neurotoxic shellfish poisoning), acute hypophosphataemia, prolonged use of neuromuscular junction blocking drugs, tick paralysis, West Nile poliomyelitis, recent diphtheria, lead intoxication, acute intermittent porphyria, functional paralysis. 
ARTICLE INFORMATION
Pure motor GBS
Same as criteria for GBS, but with absence of sensory symptoms.
Miller-Fisher syndrome (MFS)
Features required for diagnosis 
eAppendix 2. Criteria for Electrophysiologic Variants of Guillain-Barré Syndrome
At least 3 sensory nerves and 3 motor nerves with multi-site stimulation F waves, and bilateral tibial H reflexes, need to be evaluated.
AIDP
At least 1 of the following in each of at least 2 nerves, or at least 2 of the following in 1 nerve if all others inexcitable and distal compound muscle action potential (dCMAP) >10% lower limit of normal (LLN):
• Motor conduction velocity <90% LLN (85% if dCMAP <50% LLN)
• Distal motor latency >110% upper limit of normal (ULN) (>120% if dCMAP <100% LLN)
• pCMAP/dCMAP ratio <0.5 and dCMAP >20% LLN • F-response latency >120% ULN.
Demyelinating
Having some of the demyelinating features of AIDP, but not fulfilling above mentioned criteria.
AMSAN
• None of the features of AIDP except 1 demyelinating feature allowed in 1 nerve if dCMAP <10% LLN • Sensory action potential amplitudes less than LLN.
AMAN
• None of the features of AIDP except 1 demyelinating feature allowed in 1 nerve if dCMAP <10% LLN • Sensory action potential amplitudes normal.
Inexcitable
• dCMAP absent in all nerves or present in only 1 nerve with dCMAP <10%.
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